Publication | Closed Access

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

OncologyKey Patient SubgroupsMelanomaImmune Checkpoint InhibitorDermatologyCancer TreatmentImmunotherapyMedicineAdvanced MelanomaCheckmate 067